Recently, Shenzhen NewDEL Biotech Co., Ltd. ("NewDEL Biotech"）announced the completion of tens of millions of RMB in Pre-A+ round financing. This round of financing was jointly invested by Shenzhen High-Tech Investment and Hecheng Capital, among other institutions. With confidence in the company's development prospects, similar to the previous two rounds of financing, the core technical team of NewDEL Biotech continued to increase their holdings in the company at the same price. This financing will be used to advance the development of the DEL 3.0 technology platform (DNA-encoded compound library technology combined with AI), as well as for clinical trials and pre-clinical research of pipeline projects.

NewDEL Biotech is the first biopharmaceutical enterprise incubated by the Guangdong Innovation Center For Small Molecule Drug Discovery. It possesses a globally leading DEL live-cell screening technology and AI-integrated technology platform. Thanks to the trust and support from all parties and the concerted efforts of the entrepreneurial team, NewDEL Biotech has made remarkable progress in various aspects such as technology platform construction, team building, pipeline layout, and external cooperation since its establishment over two years ago. This includes the establishment of a full industry chain team from the DEL technology center for drug development to the business market department, the construction of the DEL 3.0 technology platform, and dozens of R&D pipelines. The first Class I new drug project, ND-003, has been granted FDA clinical trial approval, and business cooperation agreements have been reached with dozens of pharmaceutical companies.

At the same time, NewDEL Biotech has appointed outstanding scientists from academia, industry, and clinical sectors, including Dr. XiaoYu Li, Professor Dingke, Dr. Nick Terrett, and hospital experts, to form a first-class Scientific Advisory Committee. This committee collaborates to empower the full process of new drug development at NewDEL Biotech, forming a bidirectional flow of translational medicine and clinical feedback between basic research and clinical research, mutually reinforcing each other.

"After completing tens of millions of RMB in Pre-A round financing a year ago, we are delighted to once again receive investment from well-known investment institutions. We sincerely thank all new and existing investors for their high recognition and strong support," said Mr. He Xun, founder and chairman of NewDEL Biotech. "This financing will further accelerate the advancement of the company's technology platform and project pipeline layout. We expect to obtain IND clinical trial approval for three innovative drugs in China and the United States by the end of this year. As pharmaceutical professionals, we always orient ourselves towards unmet clinical value and strive for the ultimate goal of affordable and effective drugs for the people. To help global patients gain access to more effective and safer original drugs as soon as possible, we are accelerating our journey of breakthroughs in cutting-edge technology and advancing clinical translation tirelessly day and night."

The person in charge of Shenzhen High-Tech Investment stated: "As a Shenzhen-based enterprise, biomedicine is a key area supported by Shenzhen's '20+8' industrial policy. NewDEL Biotech's DEL 3.0 technology platform has uniqueness and differentiation, and the new technical tools will become a key factor in changing the current situation of new drug development. This investment is not only optimistic about the future development space of DEL 3.0 new drug discovery technology, but also highly recognizes the company's team. We look forward to seeing more flowers bloom on the company's technology platform, bearing abundant fruits, benefiting the people, and benefiting society."

The management of Hecheng Capital is confident about this investment: "NewDEL Biotech has a solid and stable team, efficient execution, and unique technical advantages, which ensure the timely completion of various milestones. It is certain to grow into a high-tech biotechnology company with significant technological advantages and distinct characteristics in the industry. The company currently has a complete full industry chain team, the platform technology has been very well validated, and dozens of new drug pipelines in different stages of research and development have been laid out. The FDA's clinical approval for the ND-003 project marks the company's leap from the pre-clinical stage to the clinical stage in just two years. Therefore, we have high expectations for the company's future success."

About Shenzhen High-Tech

Shenzhen High-Tech Investment Holdings Co., Ltd. (referred to as Shenzhen High-Tech Investment) was established in 1994 as a specialized financial services institution set up by the Shenzhen Municipal Party Committee and Government to address the financing difficulties faced by small and medium-sized technology enterprises. It holds the highest AAA credit rating in the capital market. Currently, the group's paid-in capital exceeds 13.8 billion yuan, with net assets of 24.3 billion yuan and total assets of 44.7 billion yuan. Its business scope includes bank loan guarantees, project guarantees, bond credit enhancement, venture capital, fund management, microfinance pawn, commercial factoring, and more, providing comprehensive investment and financing services for enterprises from the start-up stage to maturity.

For over two decades, Shenzhen High-Tech Investment has adhered to the purpose of serving small and micro technology enterprises, growing and developing together with a large number of such enterprises. Companies supported by Shenzhen High-Tech Investment, such as Huawei, BYD, Skyworth, Han's Laser, and Hikvision, have become well-known domestic and international enterprises. More than 370 companies supported by the company have been listed domestically and internationally. The company adheres to the main theme of "financial services for the real economy," explores the value potential of technology enterprises, focuses on customer-centricity, empowers innovators, and tirelessly strives to contribute to the construction of the Socialist Demonstration Zone in Shenzhen and the building of a world-leading technological powerhouse in China.

About Hecheng Capital

Zhuhai Hecheng Zhiyi Capital Management Co., Ltd. (Hecheng Capital) was founded in 2015 as a professional investment management firm dedicated to long-term value investment. As a venture capital institution, the company's core values are "harmony breeds prosperity, integrity is fundamental," adhering to the investment and incubation of innovative enterprises with "hardcore technology," and nurturing "chain-leading" enterprises with leading roles. It has successfully invested in multiple high-tech enterprises in information technology, advanced manufacturing, new materials, and biopharmaceuticals.

About NewDEL Biotechnology

Shenzhen NewDEL Biotech Co., Ltd. ("NewDEL Biotech"） established in April 2021, is an industrial company incubated and controlled by the Guangdong Innovation Center For Small Molecule Drug Discovery. Leveraging its independently developed DEL 3.0 library and unique live-cell screening technology, NewDEL Biotech focuses on addressing unmet clinical needs. It has established an innovative drug lifecycle system dedicated to FIC innovative drug design, research and development, and industrialization. The company is committed to becoming a globally leading and distinctly characterized new drug R&D biopharmaceutical company.

About Small Molecule Center

Guangdong Innovation Center For Small Molecule Drug Discovery is a provincial-level innovation incubation platform aimed at completing technology development to initial commercial applications. Focused on the innovative development needs and key technologies of the biopharmaceutical industry, it conducts independent research and development alongside collaborative efforts. The center includes the Small Molecule Drug Development Center, Large Molecule Drug Development Center, Peptide Oral Formulation Development Center, Green Synthesis Development Center, and Artificial Intelligence Development Center. It has established long-term and solid cooperation relationships with venture capital institutions, industrial parks, research institutes, industry organizations, etc. By integrating capital funds, key technologies, innovative carriers, and expert talents, it attracts the transformation and implementation of biopharmaceutical projects, thus building a complete chain system of industrial incubation services.